About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Our team
Portfolio
News
Connect
Watch Now: Dr. Christopher Janson: ASGCT Presentation on Myrtelle’s Phase 1/2 Gene Therapy Clinical Trial in Patients with Canavan Disease
Article Date
June 6, 2023
This article is featured on another website.
Go to article
Related posts
Browse all articles
November 5, 2026
Chime Biologics and Y’s AC Announce Strategic Collaboration to Advance Anti-CD26 mAb in Refractory Cancers
November 5, 2026
Chime Biologics and Y’s AC Announce Strategic Collaboration to Advance Anti-CD26 mAb in Refractory Cancers
September 11, 2026
pharmaphorum – How today’s biotechs are helping us Stand up To Cancer
September 11, 2026
pharmaphorum – How today’s biotechs are helping us Stand up To Cancer